A Systematic Review of Cost-Effectiveness Analyses Examining Treatments for Cachexia Syndrome

References

• Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793–9. doi: 10.1016/j.clnu.2008.06.013
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. doi: 10.1016/S1470-2045(10)70218-7
   PubMed Web of Science ®Google Scholar
• Meza-Valderrama D, Marco E, Dávalos-Yerovi V, Muns MD, Tejero-Sánchez M, Duarte E, Sánchez-Rodríguez D. Sarcopenia, malnutrition, and cachexia: adapting definitions and terminology of nutritional disorders in older people with cancer. Nutrients. 2021;13(3):761. doi: 10.3390/nu13030761
   PubMed Web of Science ®Google Scholar
• Arthur ST, Noone JM, Van Doren BA, Roy D, Blanchette CM. One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA. Drugs Context. 2014;3:212265. doi: 10.7573/dic.212265
   PubMedGoogle Scholar
• Baker Rogers J, Syed K, Minteer JF. Cachexia. Treasure Island (FL): StatPearls Publishing LLC; 2022.
   Google Scholar
• von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia Sarcopenia Muscle. 2014;3:507–9. doi: 10.1002/jcsm.12167
   Google Scholar
• Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle. 2013;4(3):173–8. doi: 10.1007/s13539-013-0105-y
   PubMed Web of Science ®Google Scholar
• von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1(1):1–5. doi: 10.1007/s13539-010-0002-6
   PubMed Web of Science ®Google Scholar
• Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008;11(4):400–7. doi: 10.1097/MCO.0b013e328300ecc1
   PubMed Web of Science ®Google Scholar
• Pring ET, Malietzis G, Kennedy RH, Athanasiou T, Jenkins JT. Cancer cachexia and myopenia–update on management strategies and the direction of future research for optimizing body composition in cancer—a narrative review. Cancer Treat Rev. 2018;70:245–54. doi: 10.1016/j.ctrv.2018.10.002
   PubMed Web of Science ®Google Scholar
• Grande AJ, Silva V, Maddocks M. Exercise for cancer cachexia in adults: executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle. 2015;6(3):208–11. doi: 10.1002/jcsm.12055
   PubMed Web of Science ®Google Scholar
• Von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. Int J Cardiol. 2015;184:736–42. doi: 10.1016/j.ijcard.2014.10.026
   PubMed Web of Science ®Google Scholar
• Mavropalias G, Sim M, Taaffe DR, Galvão DA, Spry N, Kraemer WJ, Häkkinen K, Newton RU. Exercise medicine for cancer cachexia: targeted exercise to counteract mechanisms and treatment side effects. J Cancer Res Clin Oncol. 2022;148(6):1389–406. doi: 10.1007/s00432-022-03927-0
   PubMed Web of Science ®Google Scholar
• Manns BJ. The role of health economics within clinical research. In: Barrett B, Parfrey P, editors. Clinical epidemiology. methods in molecular biology. Vol. 473. New York: Humana Press; 2008. p. 235–50.
   Google Scholar
• Khan S, Qamar N, Ullah I. Health economic evaluation of different treatment strategies for peripheral entrapment mononeuropathies: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021;21(5):943–52. doi: 10.1080/14737167.2021.1919088
   PubMed Web of Science ®Google Scholar
• Zhao J, Du S, Zhu Y, Liang Y, Lu J, Chang F. A systematic review of health economic evaluation on targeted therapies for first-line treatment of metastatic non-small cell lung cancer (NSCLC): quality evaluation. Cancer Manag Res. 2020;12:4357–68. doi: 10.2147/CMAR.S248471
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021:372:n71.
   PubMed Web of Science ®Google Scholar
• Strasser F. Diagnostic criteria of cachexia and their assessment: decreased muscle strength and fatigue. Curr Opin Clin Nutr Metab Care. 2008;11(4):417–21. doi: 10.1097/MCO.0b013e3283025e27
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Int J Technol Assess Health Care. 2022;38(1):e13. doi: 10.1017/S0266462321001732
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013;346:f1049–f1049. doi: 10.1136/bmj.f1049
   PubMed Web of Science ®Google Scholar
• The World Bank. World Bank Open Data; 2022. Available from: https://www.worldbank.org.
   Google Scholar
• CCEMG-EPPI. CCEMG – EPPI-Centre Cost Converter; 2019 [cited 2022] Available from: https://eppi.ioe.ac.uk/costconversion/.
   Google Scholar
• Beaston-Blaakman A, Shepard DS, Stone N, Shevitz AH. Cost-effectiveness of clinical interventions for AIDS wasting. AIDS Care. 2007;19(8):996–1001. doi: 10.1080/09540120701335238
   PubMed Web of Science ®Google Scholar
• van Wetering CR, Hoogendoorn M, Broekhuizen R, Geraerts-Keeris GJW, De Munck DRAJ, Rutten-van Mölken MPMH, Schols AMWJ. Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc. 2010;11(3):179–87. doi: 10.1016/j.jamda.2009.12.083
   PubMed Web of Science ®Google Scholar
• van Beers M, Rutten-van Mölken MPMH, van de Bool C, Boland M, Kremers SPJ, Franssen FME, van Helvoort A, Gosker HR, Wouters EF, Schols AMWJ, et al. Clinical outcome and cost-effectiveness of a 1-year nutritional intervention programme in COPD patients with low muscle mass: the randomized controlled NUTRAIN trial. Clin Nutr. 2020;39(2):405–13. doi: 10.1016/j.clnu.2019.03.001
   PubMed Web of Science ®Google Scholar
• Hall CC, Skipworth RJE, Blackwood H, Brown D, Cook J, Diernberger K, Dixon E, Gibson V, Graham C, Hall P, et al. A randomized, feasibility trial of an exercise and nutrition‐based rehabilitation programme (ENeRgy) in people with cancer. J Cachexia Sarcopenia Muscle. 2021;12(6):2034–44. doi: 10.1002/jcsm.12806
   PubMed Web of Science ®Google Scholar
• Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519–31. doi: 10.1016/S1470-2045(15)00558-6
   PubMed Web of Science ®Google Scholar
• Borsoi L, Meregaglia M, Ciani O, Tarricone R. Cost-effectiveness analysis of a potential treatment introduction for anorexia-cachexia in non-small cell lung cancer patients. Value Health. 2016;19(7):A729–A730. doi: 10.1016/j.jval.2016.09.2192
   Web of Science ®Google Scholar
• Manary M, Ndekha M, Van Oosterhout JJ. Supplementary feeding in the care of the wasted HIV infected patient. Mal Med J. 2010;22(2):46–48. doi: 10.4314/mmj.v22i2.58792
   PubMed Web of Science ®Google Scholar
• Shevitz AH, Wilson IB, McDermott AY, Spiegelman D, Skinner SC, Antonsson K, Layne JE, Beaston-Blaakman A, Shepard DS, Gorbach SL, et al. A comparison of the clinical and cost-effectiveness of 3 intervention strategies for AIDS wasting. J Acquir Immune Defic Syndr. 2005;38(4):399–406. doi: 10.1097/01.qai.0000152647.89008.2b
   PubMed Web of Science ®Google Scholar
• Dang A, Likhar N, Alok U. Importance of economic evaluation in health care: an Indian perspective. Value Health Reg Issues. 2016;9:78–83. doi: 10.1016/j.vhri.2015.11.005
   PubMedGoogle Scholar
• McCreanor V, Graves N, Barnett AG, Parsonage W, Merlo G. A systematic review and critical analysis of cost-effectiveness studies for coronary artery disease treatment. F1000Res. 2018;7:77. doi: 10.12688/f1000research.13616.2
   PubMedGoogle Scholar
• Balstad TR, Kaasa S, Solheim TS. Multimodal nutrition/anabolic therapy for wasting conditions. Curr Opin Clin Nutr Metab Care. 2014;17(3):226–35. doi: 10.1097/MCO.0000000000000045
   PubMed Web of Science ®Google Scholar
• Aversa Z, Costelli P, Muscaritoli M. Cancer-induced muscle wasting: latest findings in prevention and treatment. Ther Adv Med Oncol. 2017;9(5):369–82. doi: 10.1177/1758834017698643
   PubMed Web of Science ®Google Scholar
• Ni J, Zhang L. Cancer cachexia: definition, staging, and emerging treatments. Cancer Manag Res. 2020;12:5597–605. doi: 10.2147/CMAR.S261585
   PubMed Web of Science ®Google Scholar
• Clemente-Suárez VJ, Redondo-Flórez L, Rubio-Zarapuz A, Martínez-Guardado I, Navarro-Jiménez E, Tornero-Aguilera JF. Nutritional and exercise interventions in cancer-related cachexia: an extensive narrative review. Int J Environ Res Public Health. 2022;19(8):4604. doi: 10.3390/ijerph19084604
   PubMed Web of Science ®Google Scholar
• Little JP, Phillips SM. Resistance exercise and nutrition to counteract muscle wasting. Appl Physiol Nutr Metab. 2009;34(5):817–28. doi: 10.1139/H09-093
   PubMed Web of Science ®Google Scholar
• Passey SL, Hansen MJ, Bozinovski S, McDonald CF, Holland AE, Vlahos R. Emerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary disease. Pharmacol Ther. 2016;166:56–70. doi: 10.1016/j.pharmthera.2016.06.013
   PubMed Web of Science ®Google Scholar
• Dudgeon WD, Phillips KD, Carson JA, Brewer RB, Durstine JL, Hand GA. Counteracting muscle wasting in HIV‐infected individuals. HIV Med. 2006;7(5):299–310. doi: 10.1111/j.1468-1293.2006.00380.x
   PubMed Web of Science ®Google Scholar
• Nishie K, Sato S, Hanaoka M. Anamorelin for cancer cachexia. Drugs Today. 2022;58(3):97–104. doi: 10.1358/dot.2022.58.3.3381585
   PubMed Web of Science ®Google Scholar
• Wakabayashi H, Arai H, Inui A. The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers. J Cachexia Sarcopenia Muscle. 2021;12(1):14–6. doi: 10.1002/jcsm.12675
   PubMed Web of Science ®Google Scholar